Compare ARK Genomic Revolution ETF (ARKG) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KKR & Co Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while KKR & Co Inc trades at $110.59 (market cap $99.61B). The key difference: KKR & Co Inc pays a 0.7% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, KKR & Co Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | KKR | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $149.34 |
52-Week Low | $24.02 | $83.88 |
Market Cap | — | $99.61B |
Enterprise Value | — | $22.17B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
KKR trades at $110.625, up 6.54% today, with strong bullish momentum near its consensus price target of $127.22. Recent earnings beats in Q1 and Q2 2026, alongside a high analyst buy rating of 88.89%, reflect robust operational performance. The company's strategic acquisitions, including Medicover India and Integer Holdings, signal aggressive growth in healthcare and infrastructure sectors.
The outlook for KKR is positive, driven by earnings growth and strategic expansions, but risks include high leverage and market volatility. Upside potential exists if the company maintains its earnings trajectory and executes acquisitions successfully, though investors should monitor debt levels and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
